Abstracts tagged "prevention"

Abstract Number: 1744 • ACR Convergence 2020
The STAtins to Prevent Rheumatoid Arthritis (STAPRA) Trial: Clinical Results and Subsequent Qualitative Study, a Mixed Method Evaluation
Laurette van Boheemen¹, Marieke ter Wee², Samina Turk³, Marian van Beers³, Wouter Bos³, Diane Marsman⁴, Ed Griep⁵, Mirian Starmans⁶, Calin Popa⁷, Alper van Sijl³, Bart Seppen³, Maarten Boers⁸, Mike Nurmohamed⁹ and Dirkjan van Schaardenburg⁸, ¹Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, ²Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Antonius Ziekenhuis, Sneek, Netherlands, ⁶Zuyderland MC, Heerlen, Netherlands, ⁷Radboudumc, Nijmegen, Netherlands, ⁸Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, ⁹Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands
Background/Purpose: Persons at high risk of developing rheumatoid arthritis (RA) may benefit from a low-risk pharmacological intervention aimed at primary prevention. Previous studies demonstrated disease-modifying…
Abstract Number: 1777 • ACR Convergence 2020
Low Dose Aspirin to Prevent Pre-eclampsia in SLE Pregnancies – Counselling Helps to Realize Our Full Potential
Isabell Haase¹, Matthias Schneider¹, Ralph Brinks¹ and Rebecca Fischer-Betz¹, ¹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany
Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) face a higher risk of pre-eclampsia, especially those with additional risk factors. Low dose aspirin (LDA) is known…
Abstract Number: 1977 • ACR Convergence 2020
Delivering Fracture Prevention Through Telemedicine: A Process Evaluation
Karla Miller¹, Melissa Steffen², Aaron Seaman², Zachary Anderson¹, Janiel Green¹, Shardool Patel¹, Shylo Wardyn² and Samantha Solimeo², ¹Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ²Iowa VA Healthcare System, Iowa City, IA
Background/Purpose: Guidelines recommend osteoporosis screening using dual-energy X-ray absorptiometry (DXA) in men and women at risk for osteoporosis, but screening remains low, especially in men…
Abstract Number: 0109 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Eileen Rife¹, Emejuaiwe Nkechinyere² and Jose Leon de la Rocha³, ¹Louisiana State University, Metairie, LA, ²Department of Veterans Affairs, New Orleans, LA, ³Louisiana State University, Auburn, AL
Background/Purpose: Descriptive study designed to assess compliance to evidence-based practice guidelines for the prevention of Glucocorticoid-Induced Osteoporosis (GIOP).Methods: We queried the electronic database of the…
Abstract Number: 0111 • ACR Convergence 2020
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Amanda Stefl¹, Shikha Singla², Jessica Michaud¹, Kama Thomas², Lisa Rein² and Mary Ellen Csuka², ¹Froedtert Hospital, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
Abstract Number: 0113 • ACR Convergence 2020
Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines
Marielys Figueroa Sierra¹, Atefeh Vafa¹, Shu Cao², Yuanyuan Lu³, Helen Bateman⁴, John Carter¹, Yih Chang Lin², Raquel Cuchacovich¹, Marcos Maldonado⁴, Joanne Valeriano-Marcet¹ and Gabriela Montes-Rivera⁴, ¹University of South Florida, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, FL, ³Biostatistician at Graduate Medical Education Department, Tampa, FL, ⁴James A. Haley VA, Tampa, FL
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a potentially preventable complication in those who are maintained on glucocorticoid (GC) therapy. It is imperative to identify these patients…
Abstract Number: 0310 • ACR Convergence 2020
The Prediction of Psoriatic Arthritis Tool (PRESTO) Study – Interim Report
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁵, Christopher Ritchlin⁶, Cheryl Rosen⁷, Richard Cook² and Dafna Gladman³, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, Canada, ⁶Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…
Abstract Number: 0452 • ACR Convergence 2020
Recombinant Zoster Vaccine in Patients with Rheumatic Diseases: A Retrospective Study of 622 Patients
Tiphaine Lenfant¹, Elizabeth Kirchner², Rula Hajj-ali³, Leonard Calabrese³ and Cassandra Calabrese³, ¹Cleveland Clinic Foundation, Rocky River, OH, ²Cleveland Clinic Foundation, Cleveland, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: The recombinant herpes zoster vaccine (RZV) was FDA-approved in 2017 but patients with rheumatic diseases were excluded from initial pivotal trials because of theoretical…
Abstract Number: 0465 • ACR Convergence 2020
The COVID-19 Pandemic and Its Effect on Patients with Chronic Rheumatologic Disease Regarding the Value of Vaccination Recommendations
Rebecca Overbury¹, Gregory Stoddard² and Tracy Frech³, ¹University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: Vaccinations are an important component of care in rheumatology as many patients are immunocompromised by treatment therapies. Patients are sometimes reticent to receive recommended…
Abstract Number: 0541 • ACR Convergence 2020
Suboptimal Vaccination Coverage with Influenza, Pneumococcal and Herpes Zoster Vaccines Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases in a Nationwide Health Care Plan
Victoria Furer¹, Clara Weil², Melanie Orin², Gabriel Chodick², Varda Shalev², Yonit Fisher Shoval³, Raanan Cohen³ and Ori Elkayam⁴, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel, ³Abbvie, Hod Hasharon, Israel, ⁴Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIIRD) increase the susceptibility to infections. Immunisation against vaccine-preventable diseases is recommended for patients with AIIRD by most international medical…
Abstract Number: 0598 • ACR Convergence 2020
Impact of a Dedicated Lupus Nephritis Clinic to Improve Time to Biopsy and Care Quality
Shivani Garg¹, Callie Plafkin², Tripti Singh¹, Sarah Panzer³ and Christie Bartels⁴, ¹UW Madison, Madison, WI, ²UW Madison, Madison, ³UW-Madison, Madison, ⁴University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: Lupus nephritis (LN) contributes to a 10-fold higher risk to develop kidney failure and 26-fold higher mortality compared to peers. Kidney biopsy remains a…
Abstract Number: 1199 • 2019 ACR/ARP Annual Meeting
Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus
Nancy Desai¹, Hanni Menn-Josephy ¹, Ramon Bonegio ¹, Christina Lam ¹, Anna Kancharla ¹ and Michael York ¹, ¹Boston Medical Center, Boston
Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates…
Abstract Number: 1749 • 2019 ACR/ARP Annual Meeting
Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center
Ohoud AlAhmed¹, Amanda Way ², Shoghik akoghlanian ², Fatima Barbar-Smiley ², Stephanie Lemle ², Darby MacDonald ², Kelly Wise ², Stacy Ardoin ² and Vidya Sivaraman ³, ¹Nationwide Children's Hospital, Columbu, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used in the treatment of autoimmune diseases. However, its use is associated with progressive irreversible retinal damage and vision loss…
Abstract Number: 2105 • 2019 ACR/ARP Annual Meeting
The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids
Kengo Akashi¹, Sadao Jinno ², Akira Onishi ¹, Mai Yamashita ³, Yoko Nose ⁴, Takaichi Okano ¹, Yo Ueda ¹, Sho Sendo ¹, Jun Saegusa ¹ and Akio Morinobu ¹, ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, ³Department of Rheumatology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan, ⁴Department of Rheumatology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
Background/Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as a first-line agent of pneumocystis pneumonia (PCP) prophylaxis for those who receive prolonged high-dose glucocorticoids. Alternative agents can be…
Abstract Number: 2268 • 2019 ACR/ARP Annual Meeting
Preferences and Insights for Rheumatoid Arthritis Clinical Prevention Trial Participation
Chelsie Fleischer¹, Marie Feser ², Elizabeth Bemis ³, Christopher Striebich ⁴, LauraKay Moss ⁴, Vasilisa Kormendi ⁵, Sharon White ⁵, V. Michael Holers ⁶, Mark Harrison ⁷ and Kevin Deane ², ¹University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, ⁵University of Colorado Denver, School of Medicine, Aurora, CO USA, Aurora, CO, ⁶University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁷The University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, Vancouver, BC, Canada
Background/Purpose: In rheumatoid arthritis (RA) development, autoantibodies to citrullinated protein antigens (ACPA) are elevated in the blood before clinically-apparent synovitis develops. These findings underpin the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].